242 related articles for article (PubMed ID: 15221005)
1. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.
Yamada S; Ohira M; Horie H; Ando K; Takayasu H; Suzuki Y; Sugano S; Hirata T; Goto T; Matsunaga T; Hiyama E; Hayashi Y; Ando H; Suita S; Kaneko M; Sasaki F; Hashizume K; Ohnuma N; Nakagawara A
Oncogene; 2004 Aug; 23(35):5901-11. PubMed ID: 15221005
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal expression of CCAAT/enhancer binding proteins alpha and beta in hepatoblastomas and its prognostic significance.
Tomizawa M; Horie H; Yamamoto H; Matsunaga T; Sasaki F; Hashizume K; Hiyama E; Kaneko M; Suita S; Ando H; Hayashi Y; Ohnuma N; Nakagawara A
Oncol Rep; 2007 Feb; 17(2):341-4. PubMed ID: 17203171
[TBL] [Abstract][Full Text] [Related]
4. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma.
Zatkova A; Rouillard JM; Hartmann W; Lamb BJ; Kuick R; Eckart M; von Schweinitz D; Koch A; Fonatsch C; Pietsch T; Hanash SM; Wimmer K
Genes Chromosomes Cancer; 2004 Feb; 39(2):126-37. PubMed ID: 14695992
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma.
Shim YH; Park HJ; Choi MS; Kim JS; Kim H; Kim JJ; Jang JJ; Yu E
Mod Pathol; 2003 May; 16(5):430-6. PubMed ID: 12748249
[TBL] [Abstract][Full Text] [Related]
6. Expression of genes involved with cell cycle control, cell growth and chromatin modification are altered in hepatoblastomas.
Gray SG; Hartmann W; Eriksson T; Ekstrom C; Holm S; Kytola S; von Schweinitz D; Pietsch T; Larsson C; Kogner P; Sandstedt B; Ekstrom TJ
Int J Mol Med; 2000 Aug; 6(2):161-9. PubMed ID: 10891560
[TBL] [Abstract][Full Text] [Related]
7. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
Iolascon A; Giordani L; Moretti A; Basso G; Borriello A; Della Ragione F
Hepatology; 1998 Apr; 27(4):989-95. PubMed ID: 9537438
[TBL] [Abstract][Full Text] [Related]
8. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
[TBL] [Abstract][Full Text] [Related]
9. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.
Anna CH; Sills RC; Foley JF; Stockton PS; Ton TV; Devereux TR
Cancer Res; 2000 Jun; 60(11):2864-8. PubMed ID: 10850429
[TBL] [Abstract][Full Text] [Related]
10. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
[TBL] [Abstract][Full Text] [Related]
11. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.
Koch A; Denkhaus D; Albrecht S; Leuschner I; von Schweinitz D; Pietsch T
Cancer Res; 1999 Jan; 59(2):269-73. PubMed ID: 9927029
[TBL] [Abstract][Full Text] [Related]
12. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas.
Lee SH; Shin MS; Lee JY; Park WS; Kim SY; Jang JJ; Dong SM; Na EY; Kim CS; Kim SH; Yoo NJ
J Pathol; 1999 Jun; 188(2):207-12. PubMed ID: 10398166
[TBL] [Abstract][Full Text] [Related]
13. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma.
Bläker H; Hofmann WJ; Rieker RJ; Penzel R; Graf M; Otto HF
Genes Chromosomes Cancer; 1999 Aug; 25(4):399-402. PubMed ID: 10398436
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
Weichert W; Schmidt M; Gekeler V; Denkert C; Stephan C; Jung K; Loening S; Dietel M; Kristiansen G
Prostate; 2004 Aug; 60(3):240-5. PubMed ID: 15176053
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors.
Wirths O; Waha A; Weggen S; Schirmacher P; Kühne T; Goodyer CG; Albrecht S; Von Schweinitz D; Pietsch T
Lab Invest; 2003 Mar; 83(3):429-34. PubMed ID: 12649343
[TBL] [Abstract][Full Text] [Related]
17. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution.
Hsu HC; Cheng W; Lai PL
Cancer Res; 1997 Nov; 57(22):5179-84. PubMed ID: 9371521
[TBL] [Abstract][Full Text] [Related]
18. Upregulated genes at 2q24 gains as candidate oncogenes in hepatoblastomas.
Rodrigues TC; Fidalgo F; da Costa CM; Ferreira EN; da Cunha IW; Carraro DM; Krepischi AC; Rosenberg C
Future Oncol; 2014 Dec; 10(15):2449-57. PubMed ID: 25525853
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
Jang YJ; Kim YS; Kim WH
Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
[TBL] [Abstract][Full Text] [Related]
20. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
